Last C$0.44 CAD
Change Today 0.00 / 0.00%
Volume 0.0
ATE On Other Exchanges
As of 3:56 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

antibe therapeutics inc (ATE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - C$0.88
52 Week Low
08/29/14 - C$0.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

antibe therapeutics inc (ATE) Related Businessweek News

No Related Businessweek News Found

antibe therapeutics inc (ATE) Details

Antibe Therapeutics Inc. originates, develops, and out-licenses patent-protected pharmaceuticals for pharmaceutical and biotechnology companies. The company’s lead product includes ATB-346, a hydrogen sulfide-releasing derivative of naproxen that is in pre clinical studies for the treatment of acute and chronic joint pain, as well as to treat rheumatoid arthritis, osteoarthritis pain, ankylosing spondylitis, dysmenorrhea, dental pain, and general pain. Its products also comprise ATB-344, an indomethacin derivative to enhance the treatments for the pain associated with gout; ATB-429 for treating inflammatory bowel diseases; and GIC-1001, a hydrogen sulfide-releasing salt of trimebutine to treat irritable bowel syndrome. The company was incorporated in 2009 and is headquartered in Toronto, Canada. Antibe Therapeutics Inc. is a subsidiary of Antibe Holdings Inc.

Founded in 2009

antibe therapeutics inc (ATE) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: C$261.6K
Founder, Chief Scientific Officer and Directo...
Total Annual Compensation: C$261.6K
Chief Financial Officer
Total Annual Compensation: C$201.3K
Chief Development Officer
Total Annual Compensation: C$179.8K
Executive Vice President of Strategic Develop...
Total Annual Compensation: C$12.8K
Compensation as of Fiscal Year 2014.

antibe therapeutics inc (ATE) Key Developments

Antibe Therapeutics Inc. Completes Single Ascending Dose Portion of ATB-346 Phase I Program

Antibe Therapeutics Inc. reported that the pre-scheduled single ascending dose portion of its Phase I program has been completed and has reached its primary objectives of safety and tolerability of ATB-346, up to the maximum dose tested (1500 mg). The results of this portion of the Phase I program have met the corporation's expectations based on extensive pre-clinical studies, and support the continuation of the Phase I program into the multiple ascending dose and food-effect portions, both of which are underway and are expected to be completed by January 2015.

Antibe Therapeutics Inc. Presents at BIO-Europe 2014, Nov-04-2014 10:15 AM

Antibe Therapeutics Inc. Presents at BIO-Europe 2014, Nov-04-2014 10:15 AM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.

Antibe Therapeutics Inc., Annual General Meeting, Oct 01, 2014

Antibe Therapeutics Inc., Annual General Meeting, Oct 01, 2014., at 10:00 US Eastern Standard Time. Location: Norton Rose Fulbright Canada, Royal Bank Plaza. Agenda: To receive the financial statements of the corporation for the financial year ended March 31, 2014 together with the auditors' report thereon; to appoint auditors of the corporation and to authorize the directors to fix the remuneration of the auditors; to elect directors of the corporation; to amend the stock option plan of the corporation as described in the management information circular dated August 30, 2014; and to transact such further or other business as may properly come before the meeting or any adjournments thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATE:CN C$0.44 CAD 0.00

ATE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATE.
View Industry Companies

Industry Analysis


Industry Average

Valuation ATE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTIBE THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at